AI assistant
Diasorin AGM Information 2022
4129_dva_2022-05-02_fac5b799-35db-4120-817e-d1f306a5fb84.pdf
AGM Information
Open in viewerOpens in your device viewer
| Informazione Regolamentata n. 0957-32-2022 |
Data/Ora Ricezione 02 Maggio 2022 12:55:25 |
Euronext Milan | ||
|---|---|---|---|---|
| Societa' | : | DiaSorin | ||
| Identificativo Informazione Regolamentata |
: | 161398 | ||
| Nome utilizzatore | : | DIASORINN01 - Ulisse Spada - Valerio Vaccarone |
||
| Tipologia | : | 3.1 | ||
| Data/Ora Ricezione | : | 02 Maggio 2022 12:55:25 | ||
| Data/Ora Inizio Diffusione presunta |
: | 02 Maggio 2022 12:55:26 | ||
| Oggetto | : | votes cast | Publication of the summary report of the | |
| Testo del comunicato |
Please see the attachment.
DIASORIN: PUBLICATION OF THE SUMMARY REPORT OF THE VOTES CAST
Saluggia, May 2, 2022 – DiaSorin S.p.A. (FTSE MIB: DIA) (the "Company") hereby gives notice that, pursuant to applicable laws and regulations, the summary report of the votes cast at the ordinary meeting of shareholders of the Company, held on April 29, 2022, was made available to the public today on the Company's corporate website (www.diasoringroup.com, section "Governance", "Shareholders Meeting", "2022").
For additional information, please contact:
Corporate Vice President Communication & Investor Relations Investor Relator Tel: +39.0161.487988 Tel: +39.0161.487567 [email protected] [email protected]
Riccardo Fava Emanuela Salvini
About DiaSorin
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.
The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist". More info at www.diasoringroup.com
